Clinical trials: Hemophilia a
Hemophilia
3D Ultrasound in Hemophilic Ankles
The study examines whether a mechanical arm ultrasound system provides diagnostic accuracy comparable to expert-performed full ultrasound for detecting key joint components and whether it can reduce acquisition variability…
- Trial name
- NCT07452575
- Testing
- Mechanical Ultrasound
- Where
- Canada
- Volunteers
- 11 people
- Sponsor
- The Hospital for Sick Children
Hemophilia A, Hemophilia B
A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors
The purpose of this study was to determine the frequency of bleeding episodes in participants receiving fitusiran as prophylactic treatment of hemophilia compared to participants who were assigned to continue with their regular…
- Trial name
- ATLAS-INH (NCT03417102)
- Testing
- fitusiran, Bypassing agents
- Where
- 58 sites in United States, Australia and 15 more
- Volunteers
- 60 people
- Sponsor
- Genzyme, a Sanofi Company
Haemophilia A, Haemophilia B
Impact of Conservative Treatment by Custom-made Orthoses in Patients With Haemophilic Ankle Arthropathy
The purpose of this study intend to evaluate the effectiveness of functional orthoses (including custom-made insoles and shoes) for preventing and controlling repetitive haemarthrosis in patients suffering of haemophilic ankle…
- Trial name
- NCT00638001
- Testing
- custom-molded insoles and custom-molded shoes
- Where
- Belgium
- Volunteers
- 70 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Sonography, Haemophilia
Sonography and Haemophilia
The aim of this study is to evaluate the possibility of establishing a patient-based ultrasound monitoring of the knee (representing a target joint accessible with any hand) with a handheld device: The following questions will be…
- Trial name
- NCT04550988
- Testing
- feasibility study
- Where
- Germany
- Volunteers
- 5 people
- Sponsor
- University Hospital, Bonn
Hemophilia
Haemophilia and Bone Loss - PHILEOS Study
Haemophilia is a rare bleeding disorder, characterized by factor VIII (HA) or factor IX (HB) deficiency. The absence or the reduction of fVIII or fIX result in impaired thrombin generation and clot formation, causing excessive…
- Trial name
- PHILEOS (NCT04384341)
- Testing
- Bone densitometry (BMD), Blood sampling for patients only
- Where
- 23 sites in Belgium, Croatia and 3 more
- Volunteers
- 448 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Telemedicine, Exercise
Feasibility of a Blended Therapy Approach
Exercise is an important part of therapy guidelines in the rehabilitation of rare diseases (RDs) as Haemophilia and Myositis. The aim of this study is not to evaluate a new therapy intervention, but to evaluate the delivery of…
- Conditions
- Telemedicine, Exercise, Feasibility, Myositis
- Trial name
- bletheRD (NCT03713151)
- Testing
- Dividat FIT
- Where
- Switzerland
- Volunteers
- 30 people
- Sponsor
- University of Zurich
Glioblastoma
Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas
This study was conducted to evaluate the efficacy and safety of depatuxizumab mafodotin (ABT-414) alone or with temozolomide versus temozolomide or lomustine alone in adult participants with recurrent glioblastoma.
- Trial name
- INTELLANCE-2 (NCT02343406)
- Testing
- Depatuxizumab mafodotin, Temozolomide, Lomustine
- Where
- 102 sites in United States, Australia and 19 more
- Volunteers
- 266 people
- Sponsor
- AbbVie
Hemarthrosis, Hemophilia
Low-Cost Platelet-Rich Plasma for Hemarthropathy
Orthopedic complications can be injuries or diseases that affect the bones, muscles, and joints. Hemarthropathy is due to bleeding disorders, most commonly hemophilia, and can result in severe issues related to chronic amounts of…
- Trial name
- NCT06543368
- Testing
- Intra articular PRP Injection
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Utah
Hemophilia A
Prophylaxis Versus On-demand Therapy Through Economic Report
The project is a controlled observational, multicenter, prospective data collection on secondary prophylaxis with Kogenate Bayer in adolescents and adults with severe haemophilia A (FVIII < 1%).
- Trial name
- POTTER (NCT01159587)
- Testing
- Recombinant Factor VIII (Kogenate FS, BAY14-2222)
- Where
- Italy
- Volunteers
- 58 people
- Sponsor
- Bayer
Hemophilia, Factor XIII Deficiency
Clinical Trial of Factor XIII (FXIII) Concentrate
Congenital deficiency of Factor XIII is a rare but potentially life threatening disorder. It is inherited in an autosomal recessive fashion.
- Trial name
- NCT00640289
- Testing
- Fibrogammin P
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Children's Hospital of Orange County
Hemophilia A
BAX 855 Pediatric Study
The study purpose is: To assess the incidence of FVIII inhibitory antibodies during 6 months of twice weekly prophylactic treatment with BAX 855 or 50 exposure days (EDs), whichever occurs last.
- Trial name
- NCT02210091
- Testing
- Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method, PEGylated Recombinant Factor VIII
- Where
- 39 sites in United States, Bulgaria and 9 more
- Volunteers
- 75 people
- Sponsor
- Baxalta now part of Shire
Hemophilia A Without Inhibitor
Multidimensional Assessment of Chronic Pain in Severe Haemophilia A
Introduction: Haemophilia is a congenital coagulopathy characterised by haemarthrosis, mainly in the knees, ankles and elbows. Prophylactic treatment is the most effective therapeutic option for preventing or minimising these…
- Trial name
- NCT07096349
- Where
- Spain
- Volunteers
- 109 people
- Sponsor
- Investigación en Hemofilia y Fisioterapia
Hemophilia A
A Study to Learn More About Treatment With Damoctocog Alfa Pegol, How it is Used in Every Day Practice ("Real-World"), and How Satisfied People Who Receive Damoctocog Alfa Pegol Are in United States (US) Hemophilia Treatment Centers
People with hemophilia A do not have enough of a protein found naturally in the blood called "clotting factor 8", also known as FVIII. This protein helps the blood to clump together to prevent and stop bleeding.
- Trial name
- REAL (NCT05395858)
- Testing
- No intervention
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- Bayer
Hemophilia A, Prophylaxis of Bleeding
A Study to Learn More About the Safety of Damoctocog-alfa-pegol When Used in Routine Medical Care in Korean Participants With Hemophilia A
In this study, researchers will observe and study the data from participants with hemophilia A who receive damoctocog alfa pegol as prescribed by their doctors.
- Conditions
- Hemophilia A, Prophylaxis of Bleeding, Treatment of Bleeding
- Trial name
- NCT06222697
- Testing
- Damoctocog-alfa-pegol (Jivi, BAY94-9027)
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Bayer
Hemophilia, Chronic Synovitis
Intra-Articular Bevacizumab for Preventing Recurrent Hemarthrosis in Hemophilia With Chronic Synovitis
Hemophilia is an inherited bleeding disorder characterized by deficiency of clotting factors, leading to increased bleeding tendencies.
- Trial name
- NCT07187661
- Testing
- Intra-articular Bevacizumab
- Where
- 2 sites in Pakistan
- Volunteers
- 18 people
- Sponsor
- Khyber Medical University Peshawar
Congenital Bleeding Disorder, Haemophilia A
Safety and Pharmacokinetics of NNC 0129-0000-1003 in Subjects With Haemophilia A
This trial is conducted globally. The aim of this clinical trial is to investigate the safety and pharmacokinetics (the determination of the concentration of the administered medication in blood over time) of NNC 0129-0000-1003…
- Trial name
- pathfinder™1 (NCT01205724)
- Testing
- turoctocog alfa pegol
- Where
- 18 sites in United States, Germany and 5 more
- Volunteers
- 27 people
- Sponsor
- Novo Nordisk A/S
Hemophilia A
Individually Tailored Prophylaxis in Patients With Severe Hemophilia A
Patients with severe haemophilia A lack clotting factor FVIII and suffer from spontaneous and traumatic bleeds. In the absence of treatment, frequent bleeds in joints lead to severe joint destruction.
- Trial name
- OPTIPHASE (NCT00995046)
- Testing
- FVIII
- Where
- France
- Volunteers
- 5 people
- Sponsor
- Hospices Civils de Lyon
Hemophilia A
A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemophilia A
This study is for young children with severe hemophilia A who have previously not been treated with BAX855 or other FVIII concentrates. The main aim of the study is to check for side effects from treatment with BAX855.
- Trial name
- NCT02615691
- Testing
- PEGylated Recombinant Factor VIII, ITI
- Where
- 91 sites in United States, Austria and 21 more
- Volunteers
- 120 people
- Sponsor
- Baxalta now part of Shire
Hemophilia A
PK Driven Prophylaxis for Hemophilia A
The purpose of this study is to evaluate the implementation of pharmacokinetic (PK) driven prophylaxis in current clinical practice
- Trial name
- OBTC (NCT02634424)
- Testing
- MyPKFiT
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hemophilia A With Inhibitors
rFVIIa Prophylaxis in Children With Hemophilia A and Inhibitors
The study evaluates the efficacy and safety of a prophylactic treatment with recombinant activated FVII in reducing the frequency of joint bleeds and the development of joint damage in children with hemophilia A who develop…
- Trial name
- ENJOIH (NCT01105546)
- Testing
- recombinant activated factor VII
- Where
- 15 sites in United States, France and 4 more
- Volunteers
- 50 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico